CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026)
CytoDyn's (CYDY) quarterly Net Income towards Common Stockholders came in at -$4.7 million in Q1 2026, up 1.43% YoY from -$4.6 million in Q1 2025, and up 79.25% on a QoQ basis from -$22.6 million in Q4 2025.
Powered by 
Analysis
CytoDyn (CYDY) Net Income towards Common Stockholders (2010 - 2026) Analysis & Trends
CytoDyn (CYDY) has 17 years of Net Income towards Common Stockholders data on file, last reported at -$4.7 million in Q1 2026.
- Quarterly Net Income towards Common Stockholders rose 1.43% year-over-year to -$4.7 million in Q1 2026, while the trailing twelve-month figure through Feb 2026 was -$38.8 million (down 447.46% YoY) and the FY2025 annual result came in at $3.7 million, up 107.51% from the prior year.
- Net Income towards Common Stockholders climbed to -$4.7 million in Q1 2026, from -$22.6 million in the prior quarter.
- In the past five years, Net Income towards Common Stockholders ranged from a high of $19.2 million in Q3 2024 to a low of -$84.1 million in Q2 2022.
- A 5-year average of -$16.7 million and a median of -$11.9 million in 2024 frame the typical range for Net Income towards Common Stockholders.
- Annual changes were most pronounced in 2024 — Net Income towards Common Stockholders jumped 266.17% — and 2025, when it tumbled 374.14%.
- Tracing CYDY's Net Income towards Common Stockholders over 5 years: stood at -$26.5 million in 2022, then soared by 63.91% to -$9.6 million in 2023, then soared by 50.14% to -$4.8 million in 2024, then sank by 374.14% to -$22.6 million in 2025, then jumped by 79.25% to -$4.7 million in 2026.
- The last three Net Income towards Common Stockholders figures came in at -$4.7 million (Q1 2026), -$22.6 million (Q4 2025), and -$5.5 million (Q3 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.31 Bn | 131.46 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 85.65 Bn | 77.66 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 63.46 Bn | 58.27 Bn | 1.37 Bn | 472.00 Mn |
| 4 | Moderna | 57.94 Bn | 52.80 Bn | 52.00 Mn | -782.00 Mn |
| 5 | Revolution Medicines | 44.05 Bn | 44.05 Bn | - | -644.37 Mn |
| 6 | BeOne Medicines | 39.96 Bn | 34.86 Bn | 1.53 Bn | 237.01 Mn |
| 7 | Alnylam Pharmaceuticals | 35.16 Bn | 31.85 Bn | 992.69 Mn | 164.49 Mn |
| 8 | Royalty Pharma | 28.44 Bn | 27.60 Bn | - | 81.49 Mn |
| 9 | Insmed | 27.32 Bn | 26.16 Bn | 358.27 Mn | -13.27 Mn |
| 10 | CytoDyn | 259.28 Mn | 259.28 Mn | - | -896,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| May 31, 2026 | -896,000.00 |
| Feb 28, 2026 | -4.69 Mn |
| Nov 30, 2025 | -22.61 Mn |
| Aug 31, 2025 | -5.54 Mn |
| May 31, 2025 | -5.96 Mn |
| Feb 28, 2025 | -4.76 Mn |
| Nov 30, 2024 | -4.77 Mn |
| Aug 31, 2024 | 19.23 Mn |
| May 31, 2024 | -16.79 Mn |
| Feb 29, 2024 | -11.92 Mn |
| Nov 30, 2023 | -9.56 Mn |
| Aug 31, 2023 | -11.57 Mn |
| May 31, 2023 | -18.64 Mn |
| Feb 28, 2023 | -13.70 Mn |
| Nov 30, 2022 | -26.50 Mn |
| Aug 31, 2022 | -20.99 Mn |
| May 31, 2022 | -84.12 Mn |
| Feb 28, 2022 | -41.29 Mn |
| Nov 30, 2021 | -40.08 Mn |
| Aug 31, 2021 | -45.34 Mn |